Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 7,250 matching trials from the live ClinicalTrials.gov search.
Conditions
Generalized Myasthenia Gravis
Interventions
Pozelimab + Cemdisiran, Cemdisiran, Placebo, Pozelimab
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 16 more
Completed Phase 2Phase 3 Interventional Results available

Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis

NCT01197417
Conditions
Sickle Cell Disease
Interventions
Intravenous Magnesium Sulfate, Normal Saline Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Years to 21 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 5 more
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 6 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1021
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 643 more
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
Interventions
Fostamatinib, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more
Completed Not applicable Interventional Results available

Rheos® Pivotal Trial

NCT00442286
Conditions
Hypertension
Interventions
Rheos® Baroreflex Hypertension System
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
Exicorilant, Enzalutamide, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more
Conditions
Neuroendocrine Tumors in Lung
Interventions
Lanreotide (Autogel formulation), Placebo, Best Supportive Care
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
Conditions
Glioblastoma
Interventions
VB-111 + bevacizumab, Bevacizumab
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
48
States / cities
Birmingham, Alabama • Rogers, Arizona • Irvine, California + 40 more
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Months to 29 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
135
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
Completed No phase listed Interventional Results available

Urease Breath Test for Rapid Characterization of Pneumonia

NCT03100760
Conditions
Pneumonia, Bacterial
Interventions
13C-urea breath test
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Ischemic Stroke
Interventions
Sildenafil (Viagra), Usual care
Drug · Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Substance-Related Disorders
Interventions
Behavior Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Berkely, California • Baltimore, Maryland • Danvers, Massachusetts + 7 more
Conditions
Out of Hospital Cardiac Arrest
Interventions
ZOLL Intravascular Temperature Management System (IVTM)
Device
Lead sponsor
ZOLL Circulation, Inc., USA
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
New Britain, Connecticut • Detroit, Michigan • Royal Oak, Michigan + 6 more
Conditions
Kidney Transplantation
Interventions
Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
91
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more
Conditions
Atrial Fibrillation, Left Atrial Appendage Ligation, Pericardium, Epicardial Mapping, Heart Atria, Cardiac Surgical Procedures, Cardiac Catheterization, Pneumopericardium, Left Atrial Appendage Occlusion
Interventions
Pericardial insufflation with carbon dioxide through a transatrial microcatheter
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Post Prandial Distress Syndrome
Interventions
Placebo, 20 mg ATI 7505, 40 mg ATI 7505, 80 mg ATI 7505
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
44
States / cities
Chino, California • Fresno, California • Los Angeles, California + 37 more
Conditions
Pancreatic Cancer, Perioperative/Postoperative Complications
Interventions
vapreotide, conventional surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
18
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 13 more
Conditions
Carcinoma, Transitional Cell
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
41
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 29 more
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Conditions
Kidney Neoplasms
Interventions
epothilone b
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 3 more
Conditions
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Interventions
treprostinil SMI (treprostinil inhalation spray), Placebo (placebo inhalation spray)
Combination Product
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more
Completed Phase 3 Interventional Results available

Avelumab in First-line NSCLC (JAVELIN Lung 100)

NCT02576574
Conditions
First Line Non-Small Cell Lung Cancer
Interventions
Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
21
States / cities
Huntsville, Alabama • Surprise, Arizona • San Diego, California + 18 more